Granulocyte Colony-stimulating Factor for Preterms with Sepsis and Neutropenia: A Randomized Controlled Trial

Jasodhara Chaudhuri, Souvik Mitra, Debadatta Mukhopadhyay, Swapna Chakraborty, Sukanta Chatterjee, Jasodhara Chaudhuri, Souvik Mitra, Debadatta Mukhopadhyay, Swapna Chakraborty, Sukanta Chatterjee

Abstract

Background: Bacterial sepsis is one of the major causes of mortality in newborn infants. Mortality increases when sepsis is associated with neutropenia.

Materials and methods: We conducted a prospective, randomized, double-blind, placebo-controlled trial of recombinant human granulocyte colony-stimulating factor on preterm neonates (gestational age (GA) <34 weeks) with sepsis and absolute neutrophil count (ANC) of <1500 cells/mm(3). Mortality, duration of Neonatal Intensive Care Unit (NICU) stay, hematological parameters (ANC, platelet count, and total leukocyte count) were compared between the two groups. The GCSF group (n=39) received GCSF intravenously in a single daily dose of 10 μg/kg/day in a 5% dextrose solution over 20-40 min for three consecutive days, while the control group (n=39) received placebo of an equivalent volume of 5% dextrose.

Results: Baseline demographic profile among the two groups was comparable. Mortality rate in the GCSF group was significantly lower than in the control group (10% vs. 35%; P<0.05). By day 3 of treatment, ANC in the GCSF group was significantly higher (3521±327) compared to 2094±460 in the control group, with P value being <0.05. Duration of NICU stay also decreased significantly in the GCSF group.

Conclusion: The administration of GCSF in preterms with septicemia and neutropenia resulted in lower mortality rates. Further studies are required to confirm our results and establish this adjunctive therapy in neonatal sepsis.

Keywords: Granulocyte colony-stimulating factor; neonates; neutropenia; preterm; septicemia.

Conflict of interest statement

Conflict of Interest: None declared.

Figures

Figure 1
Figure 1
Flow of patients through the trial

References

    1. Siegel JD, McCracken GH., Jr Sepsis neonatorum. N Engl J Med. 1981;304:642–7.
    1. Polin RA, St Geme JW., 3rd Neonatal sepsis. Adv Pediatr Infect Dis. 1992;7:25–61.
    1. Philip AG, Hewitt JR. Early diagnosis of neonatal sepsis. Pediatrics. 1980;65:1036–41.
    1. Mathur NB, Singh A, Sharma VK, Satyanarayana L. Evaluation of risk factors for neonatal sepsis. Indian Pediatr. 1996;33:817–22.
    1. Banerjee MC, Seer CP. The current role of colony stimulating factors in prevention and treatment of neonatal sepsis. Semin Neonatol. 2002;7:335–49.
    1. Cairo MS. Cytokines: A new immunotherapy. Clin Perinatol. 1991;81:343–55.
    1. Fanaroff AA, Korones SB, Wright LL, Wright EC, Poland RL, Bauer CB, et al. A controlled trial of intravenous immune globulin to reduce nosocomial infections in very low birth weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med. 1994;330:1107–13.
    1. Souza LM, Boone TC, Gabrilove J, Lai PH, Zsebo KM, Murdock DC, et al. Recombinant human granulocyte colony-stimulating factor: Effects on normal and leukemic myeloid cells. Science. 1986;232:61–5.
    1. Lacy JB, Ohlsson A. Administration of intravenous immunoglobulins for prophylaxis or treatment of infection in preterm neonates: Metaanalyses. Arch Dis Child Fetal Neonatal Ed. 1995;72:151–5.
    1. Carr R, Modi N. Haemopoietic colony stimulating factors for preterm neonates. Arch Dis Child Fetal Neonatal Ed. 1997;76:F128–33.
    1. Gillian ER, Christensen RD, Suen Y, Ellis R, van de Ven C, Cairo MS. A randomised placebo controlled trial of recombinant human granulocyte macrophage colony stimulating factor administration in newborn infants with presumed sepsis: Significant induction of peripheral and bone marrow neutrophilia. Blood. 1994;84:1427–33.
    1. Kocherlakota P, La Gamma EF. Human granulocyte colony-stimulating factor may improve outcome attributable to neonatal sepsis complicated by neutropenia. Pediatrics. 1997;100:E6.
    1. Sreenan C, Osiovich H. Myeloid colony stimulating factors: Use in the newborn. Arch Pediatr Adolesc Med. 1999;153:984–8.
    1. Carr R, Brocklehurst P, Dore CJ, Modi N. Granulocyte-macrophage colony stimulating factor administered as prophylaxis for reduction of sepsis in extremely preterm, small for gestational age neonates (the PROGRAMS trial): A single-blind, multicentre, randomised controlled trial. Lancet. 2009;373:226–33.
    1. Ozdemir E, Kakehi Y, Nakamura E, Kinoshita H, Terachi T, Okada Y, et al. HLA-DRB1 *0101 and *0405 as protective alleles in Japanese patients with renal cell carcinoma. Cancer Res. 1997;57:742–6.
    1. Meherban S. 7th ed. New Delhi, India: Sagar Publications; 2010. Care of the Newborn; pp. 225–6.
    1. Manroe BL, Weinberg AG, Rosenfeld Cr, Browne R. The neonatal blood count in health and disease: Reference values for neutrophilic cells. J Pediatr. 1979;95:89–98.
    1. Kocherlakota P, La Gamma Ef. Preliminary report: RhGMCSF may reduce the incidence of neonatal sepsis in prolonged preeclampsia – associated- neutropenia. Pediatrics. 1998;102:1107–11.
    1. Kuhn P, Messer J, Paupe A, Espagne S, Kacet N, Mouchnino G, et al. A multicenter, randomised placebo–controlled trial of prophylactic recombinant granulocyte-colony stimulating factor in preterm neonates with neutropenia. J Pediatr. 2009;155:324–30.
    1. Ballard JL, Khoury JC, Wedig K, Wang L, Eilers-Walsman BL, Lipp R. New Ballard Score expanded to include extremely premature infants. J Pediatr. 1991;119:417–23.
    1. Babior BM, Stossel TP. New York, NY: Churchill Livingstone; 1984. Hematology: A pathophysiological approach; p. 167.
    1. Bilgin K, Yaramis A, Haspolat K, Taş MA, Günbey S, Derman O. A randomised trial of granulocyte-macrophage colony–stimulating factor in neonates with sepsis and neutropenia. Pediatrics. 2001;107:36–41.
    1. Gathwala G, Walia M, Bala H, Singh S. Recombinant human granulocyte colony stimulating factor in preterm neonates with sepsis and relative neutropenia: A randomised, single blind, non placebo–controlled trial. J Trop Pediatr. 2012;58:12–8.
    1. Mouzenho A, Rosenfeld CR, Sanchez PJ, Risser R. Effect of maternal hypertension on neonatal neutropenia and risk of nosocomial infection. Pediatrics. 1992;90:430–5.
    1. Devriendt K, Kim AS, Mathijs G, Frints SG, Schwartz M, Van Den Oord JJ, et al. Constitutively activating mutation in WASP causes X-linked severe congenital neutropenia. Nat Genet. 2001;27:313–7.
    1. Cairo MS. Neonatal neutrophil host defense. Prospects for immunologic enhancement during neonatal sepsis. Am J Dis Child. 1989;143:40–6.
    1. Demetri G, Griffin J. Granulocyte colony stimulating factor and its receptor. Blood. 1992;78:2791.
    1. Cairo M, Suen Y, Knoppel E, Dana R, Park L, Clark S, et al. Decreased GCSF and IL-3 production and gene expression from mononuclear cells of newborn infants. Pediatr Res. 1992;31:574–8.
    1. Omar SA, Salhadar A, Wooliever DE, Alsgaard PK. Late onset neutropenia in very low birth weight infants. Pediatrics. 2000;106:E55.
    1. Carr R, Brocklehusrst P, Dore CJ, Modi N. Granulocyte macrophage colony stimulating factor administered as prophylaxis for reduction of sepsis in extremely preterm, small for gestational neonates: A single blind, multicentre, randomized controlled trial. Lancet. 2009;373:226–33.
    1. Cairo MS, Agosti J, Ellis R, Laver JJ, Puppala B, deLemos R, et al. A randomized double blind, placebo controlled trial of prophylactic recombinant human granulocyte macrophage colony stimulating factor to reduce nosocomial infections in very low birth weight neonates. J Pediatr. 1999;134:64–70.
    1. Fanaroff AA, Stoll BJ, Wright LL, Carlo WA, Ehrenkranz RA, Stark AR, et al. Trends in neonatal morbidity and mortality for very low birth weight infants. Am J Obstet Gynecol. 2007;196:147.e1–8.
    1. Jawson MS, Jones MH, Linch DC. The effects of recombinant human granulocyte macrophage colony stimulating factor on the neutrophil respiratory burst in the term and preterm infant when studied in whole blood. Pediatr Res. 1994;36:623–7.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する